← All trials
NCT06364150
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2024
- Primary completion
- May 1, 2025
- Completion date
- Aug 1, 2026
- First posted
- Apr 15, 2024
- Last posted
- Apr 15, 2024
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Seoul National UniversityLead sponsor
- Seoul National UniversitySponsor investigator
- Seoul National UniversityOfficial
- Seoul National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.